We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

127 hedge funds and large institutions have $957M invested in Aclaris Therapeutics in 2022 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 26 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 6

85% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 26

12% more capital invested

Capital invested by funds: $851M → $957M (+$106M)

10% more funds holding

Funds holding: 115 → 127 (+12)

1% more call options, than puts

Call options by funds: $362K | Put options by funds: $357K

0.32% more ownership

Funds ownership: 95.03% → 95.35% (+0.32%)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

Holders
127
Holders Change
+12
Holders Change %
+10.43%
% of All Funds
2.19%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
19
Increased
48
Reduced
26
Closed
6
Calls
$362K
Puts
$357K
Net Calls
+$5K
Net Calls Change
-$250K

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$6.82M
2
Walleye Capital
Walleye Capital
New York
+$4.25M
3
Charles Schwab
Charles Schwab
California
+$3.91M
4
Citadel Advisors
Citadel Advisors
Florida
+$2.6M
5
BlackRock
BlackRock
New York
+$2.21M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$22.8M
2
Renaissance Technologies
Renaissance Technologies
New York
-$2.28M
3
LCM
Laurion Capital Management
New York
-$2.13M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.55M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
101
Wells Fargo
California
$97K -$3.42K -217 -3%
AIP
102
Ameritas Investment Partners
Nebraska
$71K – – –
Amundi
103
Amundi
France
$63K +$62.6K +3,975 New
MLICM
104
Metropolitan Life Insurance Company (MetLife)
New York
$57.1K – – –
UBS Group
105
UBS Group
Switzerland
$45K +$7.33K +465 +19%
O
106
OrbiMed
New York
$43.4K +$6.82M +432,934 +19%
Canada Life
107
Canada Life
Manitoba, Canada
$31K – – –
Nisa Investment Advisors
108
Nisa Investment Advisors
Missouri
$29K +$835 +53 +3%
Macquarie Group
109
Macquarie Group
Australia
$25K – – –
Simplex Trading
110
Simplex Trading
Illinois
$15K +$15.3K +972 New
HI
111
Harbour Investments
Wisconsin
$14K – – –
Royal Bank of Canada
112
Royal Bank of Canada
Ontario, Canada
$13K +$7.63K +484 +139%
CUAMC
113
China Universal Asset Management Company
China
$10K +$9.83K +624 New
PA
114
Parallel Advisors
California
$9K -$378 -24 -4%
HNWAG
115
High Net Worth Advisory Group
Florida
$8K – – –
Northwestern Mutual Wealth Management
116
Northwestern Mutual Wealth Management
Wisconsin
$8K – – –
Group One Trading
117
Group One Trading
Illinois
$7K -$31.5K -1,999 -81%
TC
118
Truvestments Capital
Florida
$5K – – –
Daiwa Securities Group
119
Daiwa Securities Group
Japan
$4K – – –
LC
120
Lindbrook Capital
California
$4K +$488 +31 +15%
S
121
SignatureFD
Georgia
$2K +$1.59K +101 New
MPWT
122
MassMutual Private Wealth & Trust
Connecticut
$1K +$236 +15 +27%
US Bancorp
123
US Bancorp
Minnesota
$1K +$1.06K +67 New
WFA
124
Wipfli Financial Advisors
Wisconsin
$1K +$1.07K +68 New
WMSA
125
Weiss Multi-Strategy Advisers
New York
– -$209K -15,000 Closed
2 3 4
5
6

ACRS Hedge Fund Activity: Q3 2022 in Review

127 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q3 2022, worth a combined $957M — up 12% from $851M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new ACRS positions and 6 closed out — a net gain of 13 holders — while 48 added to existing stakes and 26 trimmed.

The largest buyer was OrbiMed, adding an estimated $6.82M. The largest seller was Wellington Management Group, cutting an estimated $22.8M.

  • 127 institutional investors held Aclaris Therapeutics (ACRS) as of Q3 2022, up from 115 in Q2 2022.
  • Funds reported $957M of Aclaris Therapeutics stock for Q3 2022, up 12% quarter-over-quarter.
  • 19 funds opened new Aclaris Therapeutics positions in Q3 2022 and 6 closed out, a net change of +13 holders.
  • The largest Aclaris Therapeutics buyer in Q3 2022 was OrbiMed, an estimated $6.82M added.
  • The largest Aclaris Therapeutics seller in Q3 2022 was Wellington Management Group, an estimated $22.8M sold.

Based on aggregated 13F filings for Q3 2022.